Biomerica (BMRA) EBITDA (2010 - 2026)

Biomerica has disclosed EBITDA across 17 years of filings, most recently posting -$1.3 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$1.3 million, down 12.71% year-over-year; the trailing twelve-month figure through Feb 2026 was -$4.2 million (up 14.32% YoY), and the FY2025 annual result was -$5.0 million, up 16.65% from the prior year.
• EBITDA came in at -$1.3 million for Q1 2026 at Biomerica, up from -$1.3 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $4000.0 in Q3 2025 to a low of -$2.1 million in Q3 2022.
• The 5-year median for EBITDA is -$1.4 million (2024), against an average of -$1.3 million.
• Across the five-year window, EBITDA sank 1460.36% in 2023 and jumped 100.3% in 2025, its largest moves.
• Biomerica's EBITDA stood at -$1.6 million in 2022, then rose by 7.83% to -$1.5 million in 2023, then surged by 36.7% to -$954000.0 in 2024, then plunged by 38.47% to -$1.3 million in 2025, then advanced by 0.68% to -$1.3 million in 2026.
• The last three EBITDA figures came in at -$1.3 million (Q1 2026), -$1.3 million (Q4 2025), and $4000.0 (Q3 2025), per Business Quant data.